1. Considered and approved Audited Financial Results for the Quarter and Financial Year ended 31st March, 2026 along with the along with the Auditors Report thereon, Statement of Assets ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Choksi Laboratories reported full-year FY2026 revenue of ₹4,621.93 Lakhs, up 10.1% from ₹4,178.23 Lakhs in FY2025. PAT grew 29% to ₹196.43 Lakhs (vs ₹152.33 Lakhs prior year). Q4 standalone revenue was ₹1,282.22 Lakhs with PAT of ₹102.68 Lakhs. An exceptional item of ₹75.30 Lakhs was recorded from the sale of an office flat (non-recurring). The company maintained an unqualified audit opinion with no qualifications or going concern issues. Total debt increased to ₹3,017.82 Lakhs vs equity of ₹2,557.54 Lakhs (D/E ratio 1.18). Cash flow from operations declined to ₹786.48 Lakhs from ₹1,177.80 Lakhs in the prior year. The company operates in analytical testing and calibration services.
Revenue growth of 10% is modest; PAT growth of 29% is strong, boosted by a one-time exceptional item. Rising debt levels and declining operating cash flow are concerns. The clean audit opinion provides comfort to investors.